Cargando…
Blocking interaction between SHP2 and PD‐1 denotes a novel opportunity for developing PD‐1 inhibitors
Small molecular PD‐1 inhibitors are lacking in current immuno‐oncology clinic. PD‐1/PD‐L1 antibody inhibitors currently approved for clinical usage block interaction between PD‐L1 and PD‐1 to enhance cytotoxicity of CD8(+) cytotoxic T lymphocyte (CTL). Whether other steps along the PD‐1 signaling pa...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7278553/ https://www.ncbi.nlm.nih.gov/pubmed/32391629 http://dx.doi.org/10.15252/emmm.201911571 |
_version_ | 1783543357875683328 |
---|---|
author | Fan, Zhenzhen Tian, Yahui Chen, Zhipeng Liu, Lu Zhou, Qian He, Jingjing Coleman, James Dong, Changjiang Li, Nan Huang, Junqi Xu, Chenqi Zhang, Zhimin Gao, Song Zhou, Penghui Ding, Ke Chen, Liang |
author_facet | Fan, Zhenzhen Tian, Yahui Chen, Zhipeng Liu, Lu Zhou, Qian He, Jingjing Coleman, James Dong, Changjiang Li, Nan Huang, Junqi Xu, Chenqi Zhang, Zhimin Gao, Song Zhou, Penghui Ding, Ke Chen, Liang |
author_sort | Fan, Zhenzhen |
collection | PubMed |
description | Small molecular PD‐1 inhibitors are lacking in current immuno‐oncology clinic. PD‐1/PD‐L1 antibody inhibitors currently approved for clinical usage block interaction between PD‐L1 and PD‐1 to enhance cytotoxicity of CD8(+) cytotoxic T lymphocyte (CTL). Whether other steps along the PD‐1 signaling pathway can be targeted remains to be determined. Here, we report that methylene blue (MB), an FDA‐approved chemical for treating methemoglobinemia, potently inhibits PD‐1 signaling. MB enhances the cytotoxicity, activation, cell proliferation, and cytokine‐secreting activity of CTL inhibited by PD‐1. Mechanistically, MB blocks interaction between Y248‐phosphorylated immunoreceptor tyrosine‐based switch motif (ITSM) of human PD‐1 and SHP2. MB enables activated CTL to shrink PD‐L1 expressing tumor allografts and autochthonous lung cancers in a transgenic mouse model. MB also effectively counteracts the PD‐1 signaling on human T cells isolated from peripheral blood of healthy donors. Thus, we identify an FDA‐approved chemical capable of potently inhibiting the function of PD‐1. Equally important, our work sheds light on a novel strategy to develop inhibitors targeting PD‐1 signaling axis. |
format | Online Article Text |
id | pubmed-7278553 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-72785532020-06-09 Blocking interaction between SHP2 and PD‐1 denotes a novel opportunity for developing PD‐1 inhibitors Fan, Zhenzhen Tian, Yahui Chen, Zhipeng Liu, Lu Zhou, Qian He, Jingjing Coleman, James Dong, Changjiang Li, Nan Huang, Junqi Xu, Chenqi Zhang, Zhimin Gao, Song Zhou, Penghui Ding, Ke Chen, Liang EMBO Mol Med Articles Small molecular PD‐1 inhibitors are lacking in current immuno‐oncology clinic. PD‐1/PD‐L1 antibody inhibitors currently approved for clinical usage block interaction between PD‐L1 and PD‐1 to enhance cytotoxicity of CD8(+) cytotoxic T lymphocyte (CTL). Whether other steps along the PD‐1 signaling pathway can be targeted remains to be determined. Here, we report that methylene blue (MB), an FDA‐approved chemical for treating methemoglobinemia, potently inhibits PD‐1 signaling. MB enhances the cytotoxicity, activation, cell proliferation, and cytokine‐secreting activity of CTL inhibited by PD‐1. Mechanistically, MB blocks interaction between Y248‐phosphorylated immunoreceptor tyrosine‐based switch motif (ITSM) of human PD‐1 and SHP2. MB enables activated CTL to shrink PD‐L1 expressing tumor allografts and autochthonous lung cancers in a transgenic mouse model. MB also effectively counteracts the PD‐1 signaling on human T cells isolated from peripheral blood of healthy donors. Thus, we identify an FDA‐approved chemical capable of potently inhibiting the function of PD‐1. Equally important, our work sheds light on a novel strategy to develop inhibitors targeting PD‐1 signaling axis. John Wiley and Sons Inc. 2020-05-11 2020-06-08 /pmc/articles/PMC7278553/ /pubmed/32391629 http://dx.doi.org/10.15252/emmm.201911571 Text en © 2020 The Authors. Published under the terms of the CC BY 4.0 license This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Articles Fan, Zhenzhen Tian, Yahui Chen, Zhipeng Liu, Lu Zhou, Qian He, Jingjing Coleman, James Dong, Changjiang Li, Nan Huang, Junqi Xu, Chenqi Zhang, Zhimin Gao, Song Zhou, Penghui Ding, Ke Chen, Liang Blocking interaction between SHP2 and PD‐1 denotes a novel opportunity for developing PD‐1 inhibitors |
title | Blocking interaction between SHP2 and PD‐1 denotes a novel opportunity for developing PD‐1 inhibitors |
title_full | Blocking interaction between SHP2 and PD‐1 denotes a novel opportunity for developing PD‐1 inhibitors |
title_fullStr | Blocking interaction between SHP2 and PD‐1 denotes a novel opportunity for developing PD‐1 inhibitors |
title_full_unstemmed | Blocking interaction between SHP2 and PD‐1 denotes a novel opportunity for developing PD‐1 inhibitors |
title_short | Blocking interaction between SHP2 and PD‐1 denotes a novel opportunity for developing PD‐1 inhibitors |
title_sort | blocking interaction between shp2 and pd‐1 denotes a novel opportunity for developing pd‐1 inhibitors |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7278553/ https://www.ncbi.nlm.nih.gov/pubmed/32391629 http://dx.doi.org/10.15252/emmm.201911571 |
work_keys_str_mv | AT fanzhenzhen blockinginteractionbetweenshp2andpd1denotesanovelopportunityfordevelopingpd1inhibitors AT tianyahui blockinginteractionbetweenshp2andpd1denotesanovelopportunityfordevelopingpd1inhibitors AT chenzhipeng blockinginteractionbetweenshp2andpd1denotesanovelopportunityfordevelopingpd1inhibitors AT liulu blockinginteractionbetweenshp2andpd1denotesanovelopportunityfordevelopingpd1inhibitors AT zhouqian blockinginteractionbetweenshp2andpd1denotesanovelopportunityfordevelopingpd1inhibitors AT hejingjing blockinginteractionbetweenshp2andpd1denotesanovelopportunityfordevelopingpd1inhibitors AT colemanjames blockinginteractionbetweenshp2andpd1denotesanovelopportunityfordevelopingpd1inhibitors AT dongchangjiang blockinginteractionbetweenshp2andpd1denotesanovelopportunityfordevelopingpd1inhibitors AT linan blockinginteractionbetweenshp2andpd1denotesanovelopportunityfordevelopingpd1inhibitors AT huangjunqi blockinginteractionbetweenshp2andpd1denotesanovelopportunityfordevelopingpd1inhibitors AT xuchenqi blockinginteractionbetweenshp2andpd1denotesanovelopportunityfordevelopingpd1inhibitors AT zhangzhimin blockinginteractionbetweenshp2andpd1denotesanovelopportunityfordevelopingpd1inhibitors AT gaosong blockinginteractionbetweenshp2andpd1denotesanovelopportunityfordevelopingpd1inhibitors AT zhoupenghui blockinginteractionbetweenshp2andpd1denotesanovelopportunityfordevelopingpd1inhibitors AT dingke blockinginteractionbetweenshp2andpd1denotesanovelopportunityfordevelopingpd1inhibitors AT chenliang blockinginteractionbetweenshp2andpd1denotesanovelopportunityfordevelopingpd1inhibitors |